There have been tremendous efforts to make CAR T-cells more effective, safe, and persistent when treating patients. On the manufacturing side, however, errors, lot-to-lot variation, and contamination can be associated with open processes and manual handling of CAR T-cells. Cell isolation, gene editing, expansion, and cryopreservation are complex steps in a typical autologous CAR T-cell manufacturing process. Integrating this complicated multistep workflow into a closed, modular, benchtop system can facilitate transitions from laboratory scale to clinical manufacturing and improve the consistency, purity, and safety of CAR T-cell products.

In this application note you will learn about Thermo Fisher Scientific’s digitally compatible, GMP-compliant, semi-automated manufacturing platform, which when used with Gibco CTS reagents, protocols, and analytics can result in consistent and efficacious CAR T-cell production.